The Rutgers Health Scleroderma program provides comprehensive consultation for patients with systemic sclerosis (also known as scleroderma) and related disorders.
Scleroderma is a chronic, multisystem, autoimmune disease that may manifest in vasculopathy (disorders of the blood vessels), diffuse fibrosis (formation of fibrous tissue) in skin and various internal organs, and immune system abnormalities. Our program provides an initial consultation that considers the severity of illness and what is the best treatment for each patient.
We connect patients to many clinical research trials, including treatments that emphasize the use of disease-modifying agents during early signs of diffuse disease (the degree to which the disease has spread to specific areas of the body), therapies for interstitial lung disease, and new agents for severe Raynaud's phenomenon (inadequate blood flow to hands and/or feet).
Physicians who serve the Rutgers Health Scleroderma program are on the faculty of Rutgers Robert Wood Johnson Medical School, a part of Rutgers University, one of the top research institutions in America. Our doctors are active in research and teach about all aspects of scleroderma and rheumatology. Each brings leading-edge knowledge from the classroom to the exam room.
If you or a loved one seeks diagnosis and treatment for scleroderma, get in touch with the Rutgers Scleroderma program.